Ignite Creation Date:
2025-12-25 @ 4:42 AM
Ignite Modification Date:
2026-01-23 @ 8:36 AM
Study NCT ID:
NCT03127618
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-15
First Post:
2017-04-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lorlatinib - PF-06463922
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000590786', 'term': 'lorlatinib'}]}}, 'protocolSection': {'designModule': {'studyType': 'EXPANDED_ACCESS', 'expandedAccessTypes': {'individual': True}, 'nPtrsToThisExpAccNctId': 3}, 'statusModule': {'overallStatus': 'APPROVED_FOR_MARKETING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-05', 'lastUpdateSubmitDate': '2020-05-13', 'studyFirstSubmitDate': '2017-04-20', 'studyFirstSubmitQcDate': '2017-04-24', 'lastUpdatePostDateStruct': {'date': '2020-05-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-04-25', 'type': 'ACTUAL'}}, 'descriptionModule': {'briefSummary': 'Lorlatinib expanded access program'}, 'eligibilityModule': {'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Adult, Senior\n\nExclusion Criteria:\n\n\\-'}, 'identificationModule': {'nctId': 'NCT03127618', 'briefTitle': 'Lorlatinib - PF-06463922', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'orgStudyIdInfo': {'id': 'B746'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Lorlatinib', 'type': 'DRUG'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}